ChromaDex to supply pterostilbene for cancer research

ChromaDex to supply pterostilbene for cancer research

Researchers will use pTeroPure pterostilbene for preclinical in vitro and mouse model experiments.

ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced it has entered into a material transfer agreement (MTA) with the Beckman Research Institute of City of Hope whereby ChromaDex will provide BRICOH with quantities of its branded pTeroPure™ pterostilbene to be used in preclinical in vitro and mouse model experiments to study its potential therapeutic use for treatment of ovarian, uterine and breast cancer.   

According to the Center for Disease Control, over 300,000 women are diagnosed annually with breast, ovarian or uterine cancer. Second only to skin cancer, breast cancer is the most-common cancer among women.

Commenting on the announcement, Frank Jaksch, ChromaDex founder and CEO, states, "By providing materials to BRICOH for preclinical studies, we will learn more about the potential of pTeroPure's application in cancer. This relationship will complement our ongoing partnership with UC-Irvine, where we are supporting ongoing research on pTeroPure's use for nonmelanoma skin cancer."

Pterostilbene is an antioxidant that is primarily found in blueberries. Studies suggest that pterostilbene exhibits the hallmark characteristics of an effective anticancer agent based on its antineoplastic properties in several common malignancies. In vitro models have shown that pterostilbene inhibits cancer growth through alteration of the cell cycle, induction of apoptosis and inhibition of metastasis. In vivo, pterostilbene inhibits tumorigenesis and metastasis with negligible toxicity. Pterostilbene has also been shown to be effective as an inducer of antioxidant capacity in multiple cancer cell lines that may facilitate its function as an anticarcinogenic compound. Additionally, preliminary studies show that pterostilbene exhibits much greater bioavailability compared with other stilbene compounds; however, the exact pharmacologic mechanism of pterostilbene and its effects in humans are still under investigation.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.